Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- Death of Cannulation Expert, Educator and Home Dialysis Champion, Stuart Mott Posted 07-12-2024
- PD and Home HD Sessions and Posters from the 2024 NKF Spring Clinicals Posted 06-14-2024
- New, Validated Survey of Home Dialysis Patients’ Experience of Care Posted 06-14-2024
- Baxter Launches MyPD Digital Management App in Korea Posted 06-14-2024